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Abstract
The TGF-b family of mediators are thought to play important roles in the regulation of inflammation and airway remodelling
in asthma. All three mammalian isoforms of TGF-b, TGF-b1–3, are expressed in the airways and TGF-b1 and -b2 are increased
in asthma. However, there is little information on the specific roles of individual TGF-b isoforms. In this study we assess the
roles of TGF-b1 and TGF-b2 in the regulation of allergen-induced airway inflammation and remodelling associated with
asthma, using a validated murine model of ovalbumin sensitization and challenge, and isoform specific TGF-b neutralising
antibodies. Antibodies to both isoforms inhibited TGF-b mediated Smad signalling. Anti-TGF-b1 and anti-TGF-b2 inhibited
ovalbumin-induced sub-epithelial collagen deposition but anti-TGF-b1 also specifically regulated airway and fibroblast
decorin deposition by TGF-b1. Neither antibody affected the allergen-induced increase in sub-epithelial fibroblast-like cells.
Anti- TGF-b1 also specifically inhibited ovalbumin-induced increases in monocyte/macrophage recruitment. Whereas, both
TGF-b1 and TGF-b2 were involved in regulating allergen-induced increases in eosinophil and lymphocyte numbers. These
data show that TGF-b1 and TGF-b2 exhibit a combination of specific and shared roles in the regulation of allergen-induced
airway inflammation and remodelling. They also provide evidence in support of the potential for therapeutic regulation of
specific subsets of cells and extracellular matrix proteins associated with inflammation and remodelling in airway diseases
such as asthma and COPD, as well as other fibroproliferative diseases.
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Introduction
Asthma is characterised by bronchial hyperreactivity, chronic
inflammation and airway remodelling [1], with excess subepithe-
lial deposition of extracellular matrix (ECM) molecules including
collagens and proteoglycans [2–6], that correlates with increased
fibroblast/myofibroblast number [4,7,8], airway hyperresponsive-
ness [9], and reduced lung function [10]. The mechanisms
responsible for the pathologic features of asthma are incompletely
understood. However, they are generally considered to involve
complex interactions between resident and infiltrating cells and the
mediators they produce [11]. One group of mediators thought to
be central, are the transforming growth factor-b (TGF-b)
polypeptide family.
There are three mammalian isoforms, TGF-b1–3, which play
important roles in regulating inflammation, cell growth and
differentiation, including of ECM metabolism [1]. In the normal
human lung, all three isoforms are expressed by and/or localised
to the bronchial epithelium, TGF-b1 and TGF-b3 are expressed
by macrophages, and TGF-b1 is also expressed by vascular
endothelial, smooth muscle and fibroblast-like cells as well as being
bound to the sub-epithelial ECM [12–18]. In asthmatic airways, in
situ hybridization and immunohistochemical studies indicate that
TGF-b1 is increased and associated predominantly with submu-
cosal and inflammatory cells, including fibroblasts, smooth muscle
cells, eosinophils, macrophages and the airway ECM, with
variable expression associated with epithelial cells [6,10,12,14–
16,19,20]. Increased TGF-b1 expression has been attributed
predominantly to increases in eosinophils [10,20] and macro-
phages [21]. TGF-b2 immunostaining has been reported to be
increased in the asthmatic epithelium [18] with increased numbers
of TGF-b2 positive eosinophils and neutrophils in severe
asthmatics and mild asthmatics following allergen challenge
[22,23]. In addition, bronchoalveolar lavage (BAL) levels of
TGF-b1 are elevated basally in asthmatics and both TGF-b1 and
TGF-b2 are increased following allergen challenge [24,25]. There
is little information on TGF-b3 although available evidence
suggests no difference between controls and asthmatics [22,23].
There is also evidence for enhanced signalling for TGF-b family
members with increased phosphorylated Smad 2/3 [26] and
decreased Smad 7 [27] immunoreactivity.
Similar patterns of TGF-b isoform expression have been
observed in the mouse lung [13,28,29]. Animal models of asthma
have shown increased BAL and tissue levels of TGF-b1 [30,31] but
there is little information on TGF-b2 and TGF-b3. As in asthma,
allergen challenge in mice is associated with Smad 2/3 activation
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[32]. Together these data suggest potentially important roles for
TGF-b in airway inflammation and remodelling. Indeed,
inhibition of TGF-b1 or all TGF-b isoforms modulates responses
to allergen sensitisation and challenge [31,33–36] but the
conclusions have not been consistent between studies, possibly
due to differences in allergen, species or the selectivity of inhibitory
approaches.
Data from TGF-b isoform-specific knockout mice demonstrate
distinct non-redundant roles for the three TGF-b isoforms in the
lung [37–39]. However, their relative importance and specific
roles in airway inflammation and remodelling are unknown. In
this study we utilise isoform specific neutralizing antibodies to
assess the roles of TGF-b1 and TGF-b2 in inflammation and
deposition of airway subepithelial ECM molecules using a
previously validated mouse model of ovalbumin (OVA) sensitiza-
tion and challenge [40]. Isoform specific neutralising antibodies
reduced TGF-b signalling in the airways and revealed novel
isoform-specific and -shared roles in the regulation of airway
inflammation and remodelling.
Methods
Ethics Statement
Animal studies were approved by the UCL Biosciences Ethical
Review Committee and experiments carried out under appropri-
ate UK Home Office approved licence in accordance with the
Animals (Scientific Procedures) Act 1986. Animals were main-
tained in a controlled environment which included filtered air and
a 12 hour light/dark cycle. All animals had free access to food and
water.
Animal studies
Ovalbumin sensitisation and challenge was carried out using
previously validated adjuvant free methods shown to result in
increased OVA specific IgE levels, airway hyperresponsiveness,
eosinophilic inflammation, goblet cell hyperplasia and persistent
airway remodelling [40,41]. SV129/C57BL/6 mice were bred
at University College London from breeding pairs obtained
from the Jackson Laboratory. Briefly, 2–3 month old mice were
sensitised by i.p. injection of 10 mg chicken ovalbumin (grade V,
Sigma-Aldrich) in 0.1 ml normal saline or saline alone on two
occasions 10 d apart. 21 d after the second sensitisation, mice
were challenged with 6 daily intratracheal instillations of 400 mg
OVA in 50 ml normal saline or saline alone under light
halothane anaesthesia. Since previous studies had shown that
there were no inflammatory or remodelling effects in saline
sensitised/OVA challenged or OVA sensitised/saline chal-
lenged animals, these control groups were omitted from this
study [40]. Previously characterised neutralising antibodies to
TGF-b1 (CAT-192) [42], TGF-b2 (CAT-152) [43,44] or
irrelevant IgG control antibodies (CAT-001) provided by
MedImmune (formerly Cambridge Antibody Technology) and
Genzyme were injected i.p. (5 mg/kg in 0.1 ml PBS) 1d prior to
the first OVA challenge and on alternate days up to and
including 46d. Antibody dosing was based on a previously
reported effective strategy [44]. PBS vehicle was injected in
controls. Mice were killed 3, 7 or 12d after the final challenge by
i.p. injection of 0.1 ml Euthatal (200 mg pentobarbitone
sodium/ml). A longitudinal ventral incision was made in the
abdomen and the major vessels were sectioned. Lungs were
either lavaged in situ or removed and wax embedded as
described below to assess airway inflammation and remodelling.
Each group contained 6–14 animals and is indicated in the
figure legends.
Tissue preparation and staining
The lungs were inflation fixed by tracheal instillation of 4%
paraformaldehyde at 20 cm pressure, the trachea was ligated, and
the thoracic contents removed and immersed in fixative for 4 h at
4uC prior to transfer into 15% sucrose in PBS at 4uC overnight.
The lungs were rinsed in 50% ethanol/H2O and stored in 70%
ethanol/H2O prior to dehydration and wax embedding [40].
Histochemical staining
Lung sections (3 mm) were stained using modified Martius
Scarlet Blue (MSB) trichrome or haematoxylin and eosin for the
localisation of collagen and assessment of inflammatory cell
infiltration respectively.
Immunohistochemistry
Immunohistochemistry was performed on paraffin embedded
sections (5 mm) of mouse lung using antibodies to TGF-b1 (sc-146;
Santa Cruz Biotechnology), TGF-b2 (sc-90), TGF-b3 (sc-82),
pSmad 2/3 (cs3101; Cell Signaling Technology), decorin (LF-113;
kindly provided by Dr L.W. Fisher, National Institutes of Health)
and F4/80 (MCA497G; AbD Serotec). Sections were dewaxed,
rehydrated and antigen retrieval achieved by either proteinase K
digestion (20 mg/ml) for 10 minutes at room temperature (TGF-
b1, -b2, -b3) or by microwaving in 10 mM citrate buffer, pH 6, for
10 minutes (pSmad 2/3 and decorin). Sections were washed in
TBS and endogenous peroxidase blocked with 3% hydrogen
peroxide (Sigma-Aldrich) for 30 minutes at room temperature.
Sections were then washed in TBS and incubated with 4% (v/v)
goat serum (DakoCytomation) for TGF-b1, -b2, -b3 and decorin
antibodies or rabbit serum (DakoCytomation) for F4/80 antibod-
ies for 20 minutes at room temperature to block non-specific
binding sites. Excess serum was removed and the sections
incubated overnight at 4uC with primary antibodies at pre-
optimised dilutions. The sections were washed and incubated with
0.5% (v/v) goat anti-rabbit or rabbit anti-rat biotin-labelled
secondary antibodies (DakoCytomation) as appropriate for 60
minutes at room temperature. Further washes in TBS were
performed before the sections were incubated with 0.5%
streptavidin (DakoCytomation) for 30 minutes at room tempera-
ture. Excess streptavidin was removed by washing in TBS and the
sections were treated with DAB (Vector Laboratories) for 10
minutes. They were then washed in distilled water, counterstained
in Mayer’s haematoxylin, differentiated in acid alcohol, washed in
tap water, dehydrated, cleared in xylene and mounted. Negative
controls included use of isotype IgG in place of primary antibody
or pre-incubation of primary antibody with blocking peptide at 6x
the primary antibody concentration.
Image analysis
The area of airway subepithelial staining for collagen and
decorin was estimated using established methods [40]. Briefly,
sections were examined by light microscopy using a x10 objective.
Airways for analysis were selected using the following predefined
criteria. Suitable airways were: complete, of an appropriate size to
be contained within a high power field, not attached to other
airways and cut in a plane perpendicular to their length (the
minimum internal diameter: maximum internal diameter ratio
was more than 0.5 in all cases). All suitable airways in each section
were analysed. Images were captured with a digital video camera
with a resolution of 139261040 pixels (QICAM 12-bit color Fast
1394) and QCapture Pro 6.0 software (Media Cybernetics). Pixel
size was converted to micrometres and image analysis performed
using SimplePCI 6 software (Hamamatsu Corp). The airway
TGF-b and Airway Remodelling
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lumen perimeter for each suitable airway was measured. Thresh-
olding was carried out using predefined RGB criteria for
extracellular matrix components, pixels not adjoining at least 10
others were deleted, providing good definition of the airway
matrix. Staining area was calculated for each airway and results
expressed as area of sub-epithelial matrix/unit airway perimeter
(mm2/mm).
To confirm the efficacy of TGF-b neutralising antibodies,
numbers of airway epithelial cells with nuclear localised phos-
phorylated Smad 2/3 per 1000 mm airway lumen perimeter were
quantified and expressed as a percentage.
Bronchoalveolar lavage (BAL)
Following laparotomy and exsanguination, the trachea was
cannulated with a 22-gauge venflon (Ohmeda BOC) and the lungs
lavaged with 5 ml of PBS in 1060.5 ml aliquots as described
previously [45]. The BAL fluid was kept on ice throughout the
procedure and more than 90% of the instilled volume was
consistently recovered. BAL samples were centrifuged (3006g) at
4uC for 5 minutes to pellet the cells and the fluid removed. The
cell pellet was re-suspended in 500 ml of DMEM containing 10%
FBS. Total BAL cell numbers were determined using a
haemocytometer. Cytospins of BAL were prepared by centrifuging
0.5216106 cells/ml onto poly-L-lysine coated slides (Cytospin 3;
Shandon). The slides were air-dried, fixed in methanol and stained
using DiffQuik (Dade AG). At least 500 cells per sample were
differentiated, using conventional morphological criteria for
macrophages/monocytes, lymphocytes, eosinophils and neutro-
phils and expressed with respect to total cells recovered.
Assessment of fibroblast decorin production
Primary mouse lung fibroblasts[45] were seeded onto glass
coverslips in 24 well plates at a density of 20,000 cells/well in
DMEM containing 20% FBS and allowed to adhere. After 24 h
the media was replaced with fresh serum free medium with or
without TGF-b1 or -b2 (0.05–1 ng/ml, R&D Systems) for 48 h.
The media was then removed, the cell monolayer washed, air-
dried and fixed in methanol. The cells were immunostained for
decorin as described above.
Statistical analysis
Data are presented as means 6 SEM. Statistical evaluations
were performed by ANOVA and Tukey-Kramer post test for
multiple comparisons or unpaired t-tests for single comparisons
using GraphPad Prism (GraphPad Software). P-values of less than
0.05 were considered significant.
Results
TGF-b isoform localisation in normal lung and
remodelling mouse airways
The localisation of TGF-b isoforms following OVA sensitisation
and challenge, was assessed at 3, 7 and 12 d following final
challenge, using pre-validated isoform selective antibodies.
TGF-b1
In control lung TGF-b1 was associated predominantly with the
bronchial epithelium (Fig. 1A) and occasional macrophages.
Smooth muscle, endothelial and mesothelial cells, as well as the
Figure 1. Localisation of TGF-b1, -b2 and -b3 in normal and OVA challengedmouse airways. Representative images from control lungs (A, E
and I) and OVA sensitised and challenged mice 3–7 d (B, C, F, G, J and K) and 12 d (D, H and L) after final OVA challenge, immunostained (brown) for
TGF-b1 (A-D), TGF-b2 (E-H) and TGF-b3 (I-L). Different cell populations are indicated by arrows; BE - bronchial epithelial cell, F - fibroblast-like cell, G -
goblet cell, M - macrophage, Pmn - polymorphonuclear cell, ATII - type II alveolar epithelial cell. Representative images are shown from n=6–8
animals per experimental group. Scale bar represents 50 mm.
doi:10.1371/journal.pone.0009674.g001
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sub-epithelial ECM were weakly stained. Occasional fibroblast-
like cells and type II alveolar epithelial cells (AECs) were also
stained. Three and seven days following final ovalbumin challenge
goblet cell hyperplasia was observed which stained only weakly for
TGF-b1 whilst the reduced numbers of bronchial epithelial cells
remained strongly stained (Fig. 1B). In addition, there were
increased numbers of positively stained macrophages (Fig. 1B).
Increased numbers of polymorphonuclear cells (PMNs) were
present but were predominantly negative for TGF-b1 staining
(Fig. 1C). In addition, TGF-b1 staining of the sub-epithelial ECM
was weak to moderate. By 12d post challenge, goblet cell numbers
had declined and bronchial epithelial staining for TGF-b1 was
strong and similar to controls (Fig. 1A and D). Macrophages
remained strongly stained and at this time some PMNs were
positive. The subepithelial ECM was also more intensely stained
(Fig. 1D).
TGF-b2
Staining for TGF-b2 in control airways (Fig. 1E) was similar to
that for TGF-b1 although smooth muscle cells stained more
intensely compared with other cell populations and fibroblast-like
cells stained more consistently. In three and seven day post
challenge animals, goblet cells showed moderate, uniform staining
for TGF-b2 whilst bronchial epithelial cells maintained strong
staining although less intense and less numerous than in controls
(Fig. 1F). In contrast to TGF-b1, PMNs showed mixed but
predominantly positive staining for TGF-b2. Macrophages were
positive, sub-epithelial fibroblast-like cells showed mixed moderate
to negative staining and the subepithelial ECM demonstrated
weak to moderate staining (Fig. 1F). Likewise at 12d, the majority
of PMNs and macrophages (Fig. 1H) present were strongly
stained. Bronchial epithelial cells were stained for TGF-b2 (Fig. 1H)
but less intensely than in controls. Fibroblast-like cells again
showed mixed positivity and in some areas peribronchial type II
AECs were strongly stained (Fig. 1H).
TGF-b3
TGF-b3 staining was also predominantly associated with
bronchial epithelial cells in control lung although not all cells
were stained (Fig. 1I). Macrophages and smooth muscle cells were
prominently stained but staining of other cell populations which
stained positively for TGF-b1 and TGF-b2 were only sporadically
and weakly stained for TGF-b3. Three to seven days after final
challenge showed weak, diffuse staining of goblet cells (Fig. 1J) with
epithelial staining returning towards control levels by 12d (Fig. 1L).
Macrophages were generally stained, PMNs and subepithelial
fibroblast-like cells showed mixed but predominantly positive
staining (Fig. 1K) at all time-points. In contrast to TGF-b1 and
TGF-b2, TGF-b3 staining of subepithelial ECM was weak at all
times.
Inhibition of TGF-b activity reduces TGF-b signalling via
the Smad pathway
To confirm the activity of isoform specific TGF-b antibodies,
lung sections from animals 12d following final challenge were
immunostained for phosphorylated Smad 2/3. Control lung
sections showed strong nuclear localisation of staining, associated
predominantly with bronchial epithelial cells and occasional
subepithelial fibroblast-like cells in the airway sub-epithelial layer
(Figs. 2A and 3A). Staining was also prominent in type II and some
type I AECs, and macrophages (Fig. 3A). In lungs from saline and
ovalbumin sensitised and challenged animals treated with
neutralising antibodies to TGF-b1 or TGF-b2 staining intensity
Figure 2. Treatment with isoform specific TGF-b antibodies
inhibits signalling via the Smad pathway. (A-C) Representative
images of airways stained for phosphorylated Smad 2/3 (brown) from
saline sensitised and challenged mice treated with irrelevant IgG (A),
anti-TGF-b1 (B) or anti-TGF-b2 (C) 12 days after final challenge.
Phosphorylated Smad 2/3 localises to the nucleus. Note the reduction
in intensity of staining and number of positive cells in the airways of
animals treated with TGF-b antibodies (B-C) compared with controls (A).
Scale bar represents 25 mm. (D) Quantification of the proportion of
bronchial epithelial cells negative for phosphorylated Smad 2/3 in IgG
controls and saline (Sal) or ovalbumin (Ova) sensitised and challenged
animals treated with TGF-b antibodies. Each value represents the
mean 6 SEM of measurements from 9–10 animals per group. * P,0.05
or ** P,0.001 compared with control.
doi:10.1371/journal.pone.0009674.g002
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PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9674
was greatly reduced or absent in a greater proportion of cells
compared with control lungs (Fig. 2A-D). Together these data
suggest that the antibodies to TGF-b1 and TGF-b2 attained
sufficient concentrations in the lung to inhibit TGF-b signalling.
TGF-b signalling in the remodelling airway
pSmad 2/3 immunostaining was also used to examine changes in
TGF-b signalling in allergen challenged airways. Following OVA
sensitization and challenge a marked goblet cell hyperplasia was
observed at three to seven days and these cells did not stain for
pSmad 2/3, however, the basal airway epithelial cells remained
strongly positive (Fig. 3B). Peribronchial macrophages were strongly
positive and there was an increase in the number of spindle shaped
subepithelial fibroblast-like cells which showed mixed staining
(Fig. 3B). Infiltrating PMNs were generally negative.
Effect of TGF-b isoform specific inhibition on sub-
epithelial collagen deposition
To assess the effect of TGF-b isoform specific inhibition on
OVA-induced subepithelial collagen deposition 12d following final
challenge, the area of airway sub-epithelial MSB staining was
measured (Fig. 4) using previously validated methods[40]. In
vehicle control animals the area of airway sub-epithelial collagen
was 3.0260.17 mm2/mm lumen perimeter and this increased by
approximately 70% (p,0.001) in OVA exposed mice (Fig. 4C).
Treatment of animals with an IgG control antibody did not affect
basal (saline sensitised and challenged animals) or OVA-induced
collagen deposition. Similarly treatment with specific antibodies to
TGF-b1 or TGF-b2 did not significantly affect basal levels of
collagen. Antibodies to TGF-b1 or TGF-b2 inhibited the OVA-
induced increase in sub-epithelial collagen deposition by approx-
imately 60% and 70% compared with the control group (p,0.02
and p,0.01 respectively). Furthermore, the area of sub-epithelial
collagen in the airways of OVA exposed, anti-TGF-b1 or anti-
TGF-b2 treated animals was not significantly increased above that
observed in saline sensitised and challenged control animals.
Effect of TGF-b isoform specific inhibition on sub-
epithelial decorin deposition
To investigate whether ECM protein deposition is co-ordinately
regulated by TGF-b1 and TGF-b2 in airway remodelling, changes
in sub-epithelial decorin deposition were also examined (Fig. 5). In
controls, decorin deposition around the airways was less
prominent with areas of staining approximately one-third that of
collagen (0.9260.11 mm2/mm lumen perimeter). Following OVA
sensitization and challenge decorin deposition increased by
approximately 2.5 fold (p,0.001) 12 days following final
challenge. Treatment of animals with an IgG control antibody
did not affect basal or OVA-induced decorin deposition and
treatment with specific antibodies to TGF-b1 or TGF-b2 also had
no effect on basal levels of sub-epithelial decorin. Treatment of
animals with anti-TGF-b1 inhibited the OVA-induced increase in
decorin deposition by approximately 50% (p,0.01) with values
not significantly raised above those observed in saline controls. In
contrast to the effects on collagen, antibodies to TGF-b2 had no
effect on OVA-induced sub-epithelial decorin deposition.
Effect of TGF-b1 and TGF-b2 on production of decorin by
murine lung fibroblasts
To further verify the selective effect of TGF-b1 in the
regulation of decorin production, primary mouse lung fibroblasts
were cultured with TGF-b1 or TGF-b2 and their effect on
decorin production was assessed by immunocytochemistry. In
control untreated fibroblasts little or no decorin staining was
detected. However, consistent with the in vivo data, fibroblasts
incubated in the presence of TGF-b1 showed an increase in cell
associated decorin with maximal effects at 0.25–0.5 ng/ml
(Fig. 6). Whereas incubation with TGF-b2, up to 1 ng/ml,
showed no apparent increase in decorin staining, providing
further evidence that decorin synthesis is selectively regulated by
the TGF-b1 isoform.
Effect of TGF-b isoform specific inhibition on ovalbumin-
induced increase in sub-epithelial fibroblast-like cells
Staining of lung sections for pSmad 2/3 highlighted the
presence of increased numbers of sub-epithelial spindle-shaped
fibroblast-like cells (Fig. 3). Quantification showed that the
numbers of these cells almost doubled in OVA sensitised and
challenged animals compared with controls (10.7960.36 vs.
19.7260.55 cells/mm lumen perimeter; p,0.001). Inhibition of
TGF-b activity with specific antibodies to TGF-b1 or TGF-b2 did
not alter the basal or OVA-induced increase in fibroblast-like cell
number.
Figure 3. TGF-b signalling in remodelling mouse airways.
Phosphorylated Smad 2/3 staining of control (A) and remodelling (B)
mouse airway 3 days following final challenge. Cells showing active TGF-
b signalling via Smad 2/3 indicated by brown nuclear staining include
bronchial epithelial cells (BE), fibroblast-like cells (F), macrophages (M)
and type II alveolar epithelial cell (ATII). Scale bar represent 25 mm.
doi:10.1371/journal.pone.0009674.g003
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Effect of TGF-b isoform specific inhibition on ovalbumin-
induced inflammatory cell profiles
To examine changes in airway inflammation we sampled the
airway cell population by BAL 12d following final challenge. Total
cells recovered from OVA sensitised and challenged animals
increased approximately 2.5-fold (p,0.001) compared with
controls (Fig. 7). This increase included an approximate 2-fold
increase in the number of monocytes/macrophages and much
larger fold-increases in the numbers of eosinophils, lymphocytes
and neutrophils (Fig. 7). Inhibition of TGF-b1 or TGF-b2 activity
did not affect basal lavage cell profiles. Inhibition of TGF-b1 but
not TGF-b2 activity inhibited the OVA-induced increase in total
lavage cells by approximately 70% (p,0.01). This was primarily
due to a lack of monocyte/macrophage influx in OVA challenged
animals treated with anti-TGF-b1. This finding was corroborated
by immunohistochemical staining of tissue sections for the
macrophage selective cell surface marker, F4/80, which also
showed a dramatic reduction in macrophages in peribronchial
regions of OVA challenged animals treated with anti-TGF-b1
(Fig. 7). In addition, inhibition of TGF-b1 or TGF-b2 reduced the
OVA-induced increase in BAL eosinophils and lymphocytes by
approximately 50% (Fig. 7). There was no significant effect of
inhibiting TGF-b1 or TGF-b2 on OVA-induced neutrophil
numbers.
Discussion
The TGF-b family of mediators is thought to play important
roles in the pathogenesis of asthma associated with the regulation
of inflammation and airway remodelling. Although there is
evidence that expression of the different TGF-b isoforms changes
in asthma there is a lack of information on the specific roles of the
individual isoforms. Here, using an animal model and TGF-b
isoform specific neutralising antibodies, we show that TGF-b1
specifically regulates OVA-induced increases in macrophages and
also sub-epithelial deposition of decorin. In contrast, both TGF-b1
and TGF-b2 were found independently to contribute to OVA-
induced increases in eosinophils, lymphocytes and sub-epithelial
deposition of collagen (Fig. 8). We further demonstrate that
allergen-induced increases in peribronchial fibroblasts, a feature
that has previously been correlated with increased levels of TGF-b
in asthmatic airways, were not affected by selective inhibition of
TGF-b1 or TGF-b2.
In control lungs, localisation of the three TGF-b isoforms
showed broadly similar patterns to those previously described
for mouse, rat and human [12–14,16,17,28,29]. Localisation
of TGF-b1 in OVA challenged animals was similar to that
previously reported in asthmatic airways and animal models
[4,10,16,18,18,22,30,31] although at early times we found PMNs
were mostly negative for TGF-b1 and only showed positive
staining at 12d. In addition, we present novel data on TGF-b2 and
TGF-b3 localisation in OVA challenged mouse lung. The major
differences in localization compared with TGF-b1 included a
reduction in TGF-b3 staining of epithelial cells following allergen
Figure 4. TGF-b isoform shared regulation of allergen-induced
sub-epithelial collagen deposition. Control (A) and OVA sensitised
and challenged (B) mouse airways 12 days following final challenge
demonstrating allergen-induced increase in sub-epithelial collagen
deposition depicted by blue staining of the thickened airway wall
using a modified Martius Scarlet Blue stain. Scale bar represents 50 mm.
(C) Quantification of the area of collagen staining demonstrating OVA-
induced increase in sub-epithelial collagen deposition and its inhibition
by treatment with antibodies to TGF-b1 or -b2. Each value represents
the mean 6 SEM of measurements from 7–10 animals per group.
**, P,0.001 compared with relative control. +, P,0.02 and ++, P,0.01
compared with OVA control groups.
doi:10.1371/journal.pone.0009674.g004
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challenge, uniform moderate staining of goblet cells for TGF-b2
compared with very weak staining for TGF-b1 and -b3, more
consistent staining of PMNs for TGF-b2 and -b3 as well as more
consistent staining of fibroblast-like cells for TGF-b3.
These studies highlight differences in expression of the TGF-
b isoforms and also a shift in the cellular profile of TGF-b
localisation. In the normal airway, all three isoforms are
predominantly localised to the bronchial epithelium. Whereas,
following OVA sensitisation and challenge there appears to be
a shift towards decreased bronchial epithelial staining, with
increasing numbers of goblet cells staining primarily for TGF-
b2, macrophages staining for all three TGF-b isoforms, and
PMNs staining primarily for TGF-b2 and TGF-b3. These
changes, although complex, likely impact on the response to
OVA sensitisation and challenge. For example, the epithelium
is both a major source and target for TGF-b in the normal
airway. Reduced levels of epithelial TGF-b staining following
OVA may facilitate proliferation and repair, whilst increased
TGF-b production by inflammatory cells may counter this,
potentially limiting epithelial repair, facilitating epithelial-
mesenchymal transition and increasing subepithelial extracel-
lular matrix protein production (Fig. 8). In addition, the
observed isoform selective changes in cellular expression also
suggested the potential for differential roles for the three
isoforms in the regulation of inflammation and tissue
remodelling.
Previous studies in which all TGF-b isoforms were inhibited
with pan-specific antibodies or Smad 3-deficient mice, have shown
inhibition of OVA-induced sub-epithelial collagen deposition
[33,35]. Similar results have been obtained using TGF-b1 specific
antibodies [31]. Our data, using TGF-b1 specific antibodies are
consistent with these studies and in addition, show for the first time
that antibodies specific for TGF-b2 have similar inhibitory effects
on OVA-induced sub-epithelial collagen deposition. These data
suggest that TGF-b1 and -b2 are equally important in regulating
airway collagen deposition.
Figure 5. TGF-b isoform specific regulation of allergen-induced
sub-epithelial decorin deposition. Control (A) and OVA sensitised
and challenged (B) mouse airways 12 days following final challenge
demonstrating allergen-induced increase in sub-epithelial decorin
deposition depicted by brown staining of the thickened airway wall
by immunohistochemistry. Scale bar represents 50 mm. (C) Quantifica-
tion of the area of decorin staining demonstrating OVA-induced
increase in sub-epithelial decorin deposition and its inhibition by
treatment with antibodies to TGF-b1 but not TGF-b2. Each value
represents the mean 6 SEM of measurements from 9–10 animals per
group. *, P,0.001 compared with relative control. +, P,0.01 compared
with OVA control and not significantly different to the saline anti-TGF-
b1 group.
doi:10.1371/journal.pone.0009674.g005
Figure 6. Effect of TGF-b isoforms on murine lung fibroblast
decorin production. Mouse lung fibroblasts were incubated with or
without TGF-b isoforms for 48 h and decorin production assessed by
immunocytochemistry. Control cells and cells incubated with TGF-b2
showed little or no staining for decorin. In contrast cells incubated with
TGF-b1 showed increased decorin staining (brown) localised to the peri-
nuclear cytoplasm (arrows). Scale bar represents 50 mm.
doi:10.1371/journal.pone.0009674.g006
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There is increasing evidence for decorin playing a role in airway
remodelling in asthmatics [3,5,16] and animal models [40,46]. In
contrast to the coordinate regulation of collagen deposition by
TGF-b1 and TGF-b2 we show that allergen-induced decorin
deposition is selectively regulated by TGF-b1 with no apparent
role for TGF-b2 (Fig. 8). This novel finding was confirmed by in
Figure 7. TGF-b isoform shared and selective effects on allergen-induced inflammation. Graphs show total BAL cell numbers and the
relative contributions of monocytes/macrophages, eosinophils, lymphocytes and neutrophils isolated from animals 12 days following final challenge.
Each bar represents the mean6 SEM of values from 9–14 animals per group. *, P,0.05. **, P,0.01. ***, P,0.001. Photomicrographs show staining of
lung sections for the macrophage and macrophage progenitor surface antigen, F4/80, demonstrating inhibition of macrophage accumulation
(arrows) around the airways of animals treated with antibodies to TGF-b1 compared with sections from animals treated with control IgG or anti-TGF-
b2. Scale bar represents 50 mm.
doi:10.1371/journal.pone.0009674.g007
Figure 8. Schematic representation of the source and roles of TGF-b1 and TGF-b2 in OVA-induced airway inflammation and
remodelling. Following OVA sensitisation and challenge there appears to be a shift in the localisation/production of TGF-b1 (A) and TGF-b2 (B) away
from bronchial epithelial cells with increased localisation/production of TGF-b1 to macrophages and TGF-b2 to macrophages and eosinophils. TGF-b1
and TGF-b2 are potent inhibitors of bronchial epithelial proliferation, the reduced localisation of TGF-bs to these cells may be directed towards
epithelial proliferation and repair. However, greater levels of inflammatory cell derived TGF-b may counteract this. TGF-b1 is capable of inducing
epithelial-mesenchymal transition of bronchial epithelial cells in vitro but whether this occurs in this model or asthmatic airways is uncertain. TGF-b1
plays a critical role in the recruitment/maintenance of macrophages and the synthesis/deposition of decorin as well as contributing to the
recruitment/maintenance of eosinophils, lymphocytes and synthesis/deposition of collagen. TGF-b2 appears to have a more restricted role,
contributing to the recruitment/maintenance of eosinophils, lymphocytes and the synthesis/deposition of collagen. Red arrows denote synthesis/
localisation of TGF-b isoforms, blue illustrates functions of the isoforms based on this study and the literature. The width of the arrows symbolise the
apparent relative importance of the source of that isoform or its function.
doi:10.1371/journal.pone.0009674.g008
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vitro fibroblast studies. Decorin has important homeostatic roles,
being an important regulator of collagen fibrillogenesis [47], and a
natural inhibitor of TGF-b activity [48,49]. Decorin deficiency has
been shown to decrease airway resistance and increase lung
compliance [50] but decorin over-expression inhibits the devel-
opment of lung fibrosis [51], presumably at least partly through its
inhibition of TGF-b activity. Thus inhibition of decorin could
have potentially beneficial and detrimental effects in asthma
depending on the dominant mechanisms of action. Further studies
are therefore necessary to determine whether inhibition of decorin
would be beneficial in asthma.
TGF-b1 expression has previously been correlated with increased
numbers of fibroblasts/myofibroblasts in the asthmatic airway wall
[19]. In addition, studies with Smad 3 deficient mice showed
inhibition of OVA-induced peribronchial fibroblast numbers [35].
However, we found no effect of inhibiting TGF-b1 or -b2 activity
on allergen-induced fibroblast/myofibroblast-like cell number. This
suggests that mediators other than TGF-b1 and -b2, perhaps
including TGF-b3 or activin A, which also act via Smad 3, are
responsible for recruitment and proliferation of these cells.
The effects of TGF-b on inflammation are complex, having
both pro- and anti-inflammatory properties [52]. TGF-b is
thought to be involved in the recruitment and activation of
inflammatory cells in asthmatics, with further production of TGF-
b by these cells contributing to persistant airway inflammation and
remodelling [53]. Previous studies blocking TGF-b1 or TGF-b
non-specifically in OVA models have shown either reduced
inflammation [34], no effect on inflammation [31,33,35] or
increased inflammation [27,54]. The reasons for the lack of
consistency between these studies are unclear but most likely relate
to differences in the protocols and approaches to inhibit TGF-b
activity. However, in all of these studies inflammation was assessed
acutely, 24–72 hours after final challenge. In the present study
inflammation was assessed 12 days after the final OVA challenge
and as with other studies where inflammation has been assessed at
extended periods after final challenge [30] the inflammatory
profile was more mononuclear in nature (figure 7) than in acute
studies. Inhibition of TGF-b1 but not TGF-b2 completely blocked
the allergen-induced increase in monocytes/macrophages and
inhibitors of TGF-b1 or -b2 reduced allergen-induced increases in
eosinophils and lymphocytes at this time. TGF-b1 is a chemoat-
tractant for monocytes/macrophages, eosinophils and lympho-
cytes [55–57] suggesting that inhibition may reduce inflammatory
cell recruitment. Macrophages, eosinophils and lymphocyte sub-
populations, such as Th2 cells and T regulatory cells, produce
TGF-b thus inhibition of their recruitment could also limit the
allergen-induced increase in TGF-b. Consistent with these data,
inhibition of TGF-b1 or TGF-b1 and TGF-b2 have previously
been shown to reduce monocyte/macrophage numbers in
cutaneous wound healing [58]. In addition, the reduction in the
OVA-induced monocyte/macrophage numbers associated with
the inhibition of TGF-b1 may contribute to the reduced
subepithelial deposition of extracellular matrix proteins since
previous studies have shown that macrophage depletion inhibits
the development of fibrosis in other tissues including liver and lung
parenchyma [59,60].
These studies were carried out with the widely used OVA
sensitisation and challenge model. Whilst it is recognised that this
does not mimic asthma, it does replicate many of the characteristic
features of the disease [61]. In the current study we demonstrate
that localisation of TGF-b isoforms in control and OVA exposed
airways are generally consistent with currently available data in
normal and asthmatic human airways. In addition, we have
previously shown airway remodelling observed at 12d in this
model persists until at least 28d [40]. Together, these data suggest
that the model was appropriate for the current studies.
Although, as far as we are aware, this is the first study to identify
TGF-b isoform specific effects in the lung there are earlier
precedents both in vitro and in vivo. TGF-b1 is an isoform specific
regulator of osteodifferentiation [62]. TGF-b2 is a specific inducer
of hair follicle morphogenesis [63] and of differentiation of cardiac
myocytes from embryonic stem cells [64]. TGF-b3 specifically
regulates palate fusion [65].
The mechanisms responsible for TGF-b isoform specific effects
are currently unknown. There are multiple points in the pathway
from synthesis, through activation, accessory molecule and
receptor binding, to signalling which may lead to isoform specific
effects [1]. However, neutralising antibodies act on the active
peptide hence the isoform specific effects observed in this study
most likely relate to altered dynamics between accessory
molecules, such as betaglycan and endoglin, and differences in
receptor affinities for the uninhibited isoforms. In addition, TGF-b
isoforms are capable of inducing expression of the other isoforms
thus inhibition may further alter relative isoform expression.
Further studies are required to elucidate these potentially complex
mechanisms.
In summary, we have demonstrated for the first time that TGF-
b isoforms have a combination of specific and shared roles in the
regulation of airway inflammation and remodelling (Fig. 8). This
provides evidence in support of the potential for therapeutic
regulation of specific subsets of cells and extracellular matrix
components in inflammation and remodelling associated with
airway disease such as asthma and possibly other inflammatory
and fibroproliferative diseases.
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